BETHESDA, MD 25 October 2011—Users of AHFS Drug Information® (AHFS DI®) should be aware of a correction to the monograph on infliximab.
The error appears in the first column on page 3720 of the printed edition of AHFS DI 2011® under the subhead Pretreatment Regimen, Rate Titration Schedule, and Patient Monitoring, in Dosage and Administration: Reconstitution and Administration. In the last sentence in the second paragraph under this subhead, the statement should read:
"Infliximab infusions should be administered IV over at least 2 hours. IV infusions can be given at a rate of 2 mL/minute or, alternatively, a rate titration schedule may be used in an attempt to prevent or ameliorate acute infusion reactions. If a rate titration schedule is used in patients who are receiving an initial infliximab dose, those without a history of acute infusion reactions to prior doses of the drug, or those with a history of such reactions, the manufacturer recommends that the IV infusion be initiated at a rate of 10 mL/hour for the first 15 minutes followed by 20 mL/hour for 15 minutes, 40 mL/hour for 15 minutes, 80 mL/hour for 15 minutes, 150 mL/hour for 30 minutes, and then 250 mL/hour for 30 minutes." [emphasis added]
The originally stated infusion rate of 80 mL/minute is incorrect. The correct infusion rate is 80 mL/hour.
Log in at http://ahfsdruginformation.com for the revised AHFS and Essentials monographs on bivalirudin.
